This is the authors' abstract. We don't add key points for this paper.
Introduction Tumor genomic profiling (TGP) is used to optimize cancer treatment but is underutilized by Black patients, despite having disproportionately higher cancer morbidity and mortality. No interventions using electronic health decision support tools (eHealth DSTs) have been developed to assist patients with understanding this test or address barriers to uptake and communicating preferences with a doctor. Methods Using the Ottawa Decision Support Framework, we systematically developed the Gene Pilot eHealth DST with Black cancer patients. We conducted qualitative focus groups (five groups, N = 33) and surveys ( N = 121), elicited community advisory board feedback ( N = 10) to devise DST content and communication strategies, and then conducted user testing ( N = 10). Content was informed by commercial marketing techniques - segmentation, perceptual mapping, vector message modeling – to elucidate how medical mistrust was an important construct to address in Gene Pilot. Results User testing (1–7 scale) indicated Gene Pilot was highly accepted, including ease of use (M = 6.67, SD = 0.50), that it addressed important barriers such as medical mistrust and genetic literacy (6.63, SD = 0.52), and allowed patients to prepare for the decision (M = 6.44, SD = 0.73) and to communicate with their doctor (M = 6.33, SD = 0.73). Suggestions for improved navigability were addressed. Conclusion Overall, Gene Pilot was found to be acceptable, suggesting its readiness for efficacy testing.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Bass et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: